Isoray, Inc. /
Viewpoint Molecular Targeting, Inc.
Isoray completes merger with Viewpoint Molecular Targeting
- Terms
- Not stated
- Stage
- Closed




What happened
Isoray, Inc. completed its merger with Viewpoint Molecular Targeting, Inc. on Feb. 3, 2023. Viewpoint continues as a wholly owned subsidiary of Isoray.
Viewpoint develops oncology therapeutics and complementary imaging agents as an alpha-particle radiopharmaceutical company.
The source
Everything on this page comes from the source below.
Isoray completes merger with Viewpoint Molecular Targeting
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly